Literature DB >> 14656464

Generation and characterization of single-chain antibody fragments specific against transmembrane envelope glycoprotein gp46 of maedi-visna virus.

Dalibor Blazek1, Vladimir Celer, Iva Navrátilová, Petr Skládal.   

Abstract

A single-chain antibody fragments (scFv) was developed directed against transmembrane envelope glycoprotein gp46 of the virus maedi-visna, by the application of the antibody phage display library. To get specific scFv binders, the library was panned against the biotinylated peptide of 20 amino acids corresponding to the principal immunodominant domain of gp46 protein. The number of positively binding scFvs was evaluated by scFv-phage ELISA, BstN1 fingerprinting and DNA sequencing. The scFvs were expressed in soluble form and purified by immobilized metal affinity chromatography (IMAC) with a yield of 2-2.5 mg/l. Two scFvs have shown to recognize gp46 and gp150 proteins in Western blot analysis. The scFvs also recognized the virus in infected cells as shown by immunofluorescence assay. The affinity of the obtained antibody fragments to gp46 peptide was measured by surface plasmon resonance, and the resulting K(A) was in the 10(6)-10(7)lmol(-1) range. The application of characterized scFvs for expression as intrabodies in intracellular immunization against virus maedi-visna infection and for the diagnosis of this virus is discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14656464     DOI: 10.1016/j.jviromet.2003.09.020

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  9 in total

1.  Recombinant single chain Fv antibodies specific for glycoprotein D of equid herpesvirus 1.

Authors:  D Molinková; V Celer
Journal:  Folia Microbiol (Praha)       Date:  2006       Impact factor: 2.099

2.  Diabodies targeting epithelial membrane protein 2 reduce tumorigenicity of human endometrial cancer cell lines.

Authors:  Kaori Shimazaki; Eric J Lepin; Bo Wei; Agnes K Nagy; Catherine P Coulam; Sergey Mareninov; Maoyong Fu; Anna M Wu; James D Marks; Jonathan Braun; Lynn K Gordon; Madhuri Wadehra
Journal:  Clin Cancer Res       Date:  2008-11-15       Impact factor: 12.531

3.  Phage display on the base of filamentous bacteriophages: application for recombinant antibodies selection.

Authors:  N V Tikunova; V V Morozova
Journal:  Acta Naturae       Date:  2009-10       Impact factor: 1.845

Review 4.  Applying Antibodies Inside Cells: Principles and Recent Advances in Neurobiology, Virology and Oncology.

Authors:  Congcong Zhang; Rina M Ötjengerdes; Julian Roewe; Rebeca Mejias; Andrea L J Marschall
Journal:  BioDrugs       Date:  2020-08       Impact factor: 5.807

5.  Identification of single-chain antibody fragments specific against SARS-associated coronavirus from phage-displayed antibody library.

Authors:  Zheng-Xue Liu; Guo-Hua Yi; Yi-Peng Qi; Ying-Le Liu; Jun-Peng Yan; Juan Qian; En-Qi Du; Wei-Fang Ling
Journal:  Biochem Biophys Res Commun       Date:  2005-04-08       Impact factor: 3.575

6.  Intracellular human antibody fragments recognizing the VP35 protein of Zaire Ebola filovirus inhibit the protein activity.

Authors:  Michela Flego; Aldo Frau; Luisa Accardi; Alessandra Mallano; Alessandro Ascione; Mara Gellini; Elisa Fanunza; Stefano Vella; Paola Di Bonito; Enzo Tramontano
Journal:  BMC Biotechnol       Date:  2019-09-05       Impact factor: 2.563

Review 7.  Blocking translocation of cell surface molecules from the ER to the cell surface by intracellular antibodies targeted to the ER.

Authors:  Thomas Böldicke
Journal:  J Cell Mol Med       Date:  2007 Jan-Feb       Impact factor: 5.310

Review 8.  Specific in vivo knockdown of protein function by intrabodies.

Authors:  Andrea L J Marschall; Stefan Dübel; Thomas Böldicke
Journal:  MAbs       Date:  2015-08-07       Impact factor: 5.857

Review 9.  Phage Display Derived Monoclonal Antibodies: From Bench to Bedside.

Authors:  Mohamed A Alfaleh; Hashem O Alsaab; Ahmad Bakur Mahmoud; Almohanad A Alkayyal; Martina L Jones; Stephen M Mahler; Anwar M Hashem
Journal:  Front Immunol       Date:  2020-08-28       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.